Our Team
Our team is responsible for IGC-AD1 that is in Phase 2 for Alzheimer’s disease and MINT-AD, an AI tool for risk stratification and prediction of cognitive decline. We unite science and care for patients and caregivers worldwide.
Meet the Founders:
The Vision to Transform Alzheimer's Care
Ram Mukunda
Ram Mukunda leads the company’s mission to treat Alzheimer’s through innovative science. He’s guiding a Phase 2 clinical trial for IGC-AD1, targeting agitation in Alzheimer’s patients. With a background in engineering and mathematics, he merges biotech strategy with early AI-powered drug discovery. Ram has over two decades of leadership experience across public companies and emerging technologies. He is passionate about transforming neurodegenerative care globally.
Visit LinkedIn →
Claudia Grimaldi
Claudia Grimaldi is a Vice President and Director, where she oversees international teams across preclinical research, regulatory compliance, and trial operations. She plays a key role in managing IGC’s FDA-registered Alzheimer’s trials. Claudia brings a unique blend of psychological insight and operational rigor to her leadership. Her work builds critical bridges between scientists, clinicians, and advisors worldwide. She holds an MBA and has extensive experience in healthcare management.
Visit LinkedIn →
Meet the
Board
Meet the leaders shaping our vision: industry experts guiding IGC Pharma’s future in Alzheimer’s care.
Richard
Prins
Chairman
30+ years in private equity and investment banking. Board expert in audit and governance, with 200+ global transactions across multiple industries.
Visit LinkedIn →
Jim
Moran
Director
Former U.S. Representative and Mayor with 30+ years in public service. Expert in policy, governance, and community leadership across Virginia.
Visit LinkedIn →
Terry
Lierman
Director
Health policy leader with 35+ years’ experience. Founded major health orgs like PanCAN and led NIH-related boards and medical research initiatives.
Visit LinkedIn →
Meet
the Advisors
World-class scientific and medical advisors guiding our breakthroughs in Alzheimer’s and brain health.
